Quick Answer
Zentalis Pharmaceuticals, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
Zentalis Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $0.00 -100.0% |
$67.42M | $0.00 | $0.00 | — | — |
| Revenue (ASC 606) | $0.00 -100.0% |
$67.42M | $0.00 | $0.00 | — | — |
| Net Income | -$137.06M +17.4% |
-$165.84M +43.2% |
-$292.19M -23.4% |
-$236.81M -49.2% |
-$158.72M -34.7% |
-$117.84M -158.1% |
| Diluted EPS | -$1.91 +18.0% |
-$2.33 +47.9% |
-$4.47 +0.2% |
-$4.48 -20.4% |
-$3.72 +11.2% |
-$4.19 +48.7% |
| Total Assets | $288.97M -32.9% |
$430.34M -22.0% |
$551.69M +2.3% |
$539.31M +18.7% |
$454.51M +24.3% |
$365.56M +317.9% |
| Cash and Equivalents | $35.99M +6.2% |
$33.90M +20.9% |
$28.04M -34.9% |
$43.07M -27.9% |
$59.71M +8.7% |
$54.95M -18.3% |
| Stockholders Equity | $216.20M -35.9% |
$337.19M -22.9% |
$437.28M +0.8% |
$433.80M +19.0% |
$364.48M +9.3% |
$333.38M +554.9% |
| R&D Expense | $107.30M -36.0% |
$167.77M -11.5% |
$189.59M +9.8% |
$172.73M -1.6% |
$175.60M +106.8% |
$84.90M +121.2% |
| Operating Income | -$152.81M +20.1% |
-$191.19M +36.2% |
-$299.51M -31.8% |
-$227.29M -5.0% |
-$216.54M -82.3% |
-$118.79M -153.6% |
| Shares Outstanding | 69.09M -3.1% |
71.28M +0.7% |
70.77M +19.4% |
59.28M +30.3% |
45.49M +10.8% |
41.04M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | — | — |
| Revenue (ASC 606) | September 30, 2025 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$26.69M | +33.5% | +0.7% |
| Diluted EPS | September 30, 2025 | -$0.37 | +33.9% | +0.0% |
| Total Assets | September 30, 2025 | $327.25M | -27.4% | -7.0% |
| Cash and Equivalents | September 30, 2025 | $39.07M | -5.4% | +3.9% |
| Stockholders Equity | September 30, 2025 | $252.87M | -28.6% | -7.9% |
| R&D Expense | September 30, 2025 | $22.95M | -37.7% | -16.9% |
| Operating Income | September 30, 2025 | -$33.73M | +34.4% | +6.4% |
| Shares Outstanding | September 30, 2025 | 72.25M | +1.5% | +0.2% |
- Zentalis Pharmaceuticals, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
- Zentalis Pharmaceuticals, Inc. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- Zentalis Pharmaceuticals, Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2025.
- Zentalis Pharmaceuticals, Inc. showed a decrease of -100.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Zentalis Pharmaceuticals, Inc. reported Net Income of -$137.06 million for fiscal year 2025.
- Zentalis Pharmaceuticals, Inc. showed an increase of +17.4% in Net Income compared to the prior fiscal year.
- Zentalis Pharmaceuticals, Inc. reported Diluted EPS of $1.91 per share (loss) for fiscal year 2025.
- Zentalis Pharmaceuticals, Inc. showed an increase of +18.0% in Diluted EPS compared to the prior fiscal year.
- Zentalis Pharmaceuticals, Inc. reported Total Assets of $288.97 million for fiscal year 2025.
- Zentalis Pharmaceuticals, Inc. showed a decrease of -32.9% in Total Assets compared to the prior fiscal year.
- Zentalis Pharmaceuticals, Inc. reported Cash and Equivalents of $35.99 million for fiscal year 2025.
- Zentalis Pharmaceuticals, Inc. showed an increase of +6.2% in Cash and Equivalents compared to the prior fiscal year.
- Zentalis Pharmaceuticals, Inc. reported Stockholders Equity of $216.20 million for fiscal year 2025.
- Zentalis Pharmaceuticals, Inc. showed a decrease of -35.9% in Stockholders Equity compared to the prior fiscal year.
- Zentalis Pharmaceuticals, Inc. reported R&D Expense of $107.30 million for fiscal year 2025.
- Zentalis Pharmaceuticals, Inc. showed a decrease of -36.0% in R&D Expense compared to the prior fiscal year.
- Zentalis Pharmaceuticals, Inc. reported Operating Income of -$152.81 million for fiscal year 2025.
- Zentalis Pharmaceuticals, Inc. showed an increase of +20.1% in Operating Income compared to the prior fiscal year.
- Zentalis Pharmaceuticals, Inc. reported Shares Outstanding of 69.09 million shares for fiscal year 2025.
- Zentalis Pharmaceuticals, Inc. showed a decrease of -3.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: